Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

First Posted Date
2015-12-23
Last Posted Date
2020-03-19
Lead Sponsor
Samsung Medical Center
Target Recruit Count
90
Registration Number
NCT02638428
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

First Posted Date
2015-12-21
Last Posted Date
2024-03-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
60
Registration Number
NCT02636322
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

First Posted Date
2015-12-17
Last Posted Date
2024-07-25
Lead Sponsor
Institut de Recherches Internationales Servier
Target Recruit Count
153
Registration Number
NCT02632708
Locations
🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

and more 14 locations

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

First Posted Date
2015-12-17
Last Posted Date
2023-12-05
Lead Sponsor
Fudan University
Target Recruit Count
1
Registration Number
NCT02633514
Locations
🇨🇳

Kailiang Wu, Shanghai, Shanghai, China

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

First Posted Date
2015-12-16
Last Posted Date
2016-08-04
Lead Sponsor
Beijing Friendship Hospital
Target Recruit Count
120
Registration Number
NCT02631109
Locations
🇨🇳

Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma

First Posted Date
2015-12-16
Last Posted Date
2021-08-25
Lead Sponsor
Ruijin Hospital
Target Recruit Count
256
Registration Number
NCT02631239
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia

First Posted Date
2015-12-16
Last Posted Date
2018-02-23
Lead Sponsor
Alison Sehgal, MD, MS
Target Recruit Count
1
Registration Number
NCT02631252
Locations
🇺🇸

University of Pittsburgh Cancer Institute - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

First Posted Date
2015-12-11
Last Posted Date
2024-07-01
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
30
Registration Number
NCT02628405
Locations
🇺🇸

Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States

🇺🇸

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States

🇺🇸

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States

and more 9 locations

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

First Posted Date
2015-12-10
Last Posted Date
2023-12-20
Lead Sponsor
Arog Pharmaceuticals, Inc.
Target Recruit Count
16
Registration Number
NCT02626338
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

Houston Methodist, Houston, Texas, United States

🇺🇸

University of Arkansas, Little Rock, Arkansas, United States

and more 1 locations

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

First Posted Date
2015-11-16
Last Posted Date
2024-07-19
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
12
Registration Number
NCT02605421
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy